Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects


Yang Yi-Ping,Lee Andy Chi-Lung,Lin Liang-TingORCID,Chen Yi-Wei,Huang Pin-I,Ma Hsin-I,Chen Yi-Chen,Lo Wen-LiangORCID,Lan Yuan-Tzu,Fang Wen-Liang,Wang Chien-Ying,Liu Yung-Yang,Hsu Po-KueiORCID,Lin Wen-Chang,Li Chung-PinORCID,Chen Ming-Teh,Chien Chian-ShiuORCID,Wang Mong-LienORCID


Peptide drugs that target protein–protein interactions have attracted mounting research efforts towards clinical developments over the past decades. Increasing reports have indicated that expression of Musashi 1 (MSI1) is tightly correlated to high grade of cancers as well as enrichment of cancer stem cells. Treatment failure in malignant tumors glioblastoma multiform (GBM) had also been correlated to CSC-regulating properties of MSI1. It is thus imperative to develop new therapeutics that could effectively improve current regimens used in clinics. MSI1 and AGO2 are two emerging oncogenic molecules that both contribute to GBM tumorigenesis through mRNA regulation of targets involved in apoptosis and cell cycle. In this study, we designed peptide arrays covering the C-terminus of MSI1 and identified two peptides (Pep#11 and Pep#26) that could specifically interfere with the binding with AGO2. Our Biacore analyses ascertained binding between the identified peptides and AGO2. Recombinant reporter system Gaussian luciferase and fluorescent bioconjugate techniques were employed to determine biological functions and pharmacokinetic characteristics of these two peptides. Our data suggested that Pep#11 and Pep#26 could function as decoy peptides by mimicking the interaction function of MSI1 with its binding partner AGO2 in vitro and in vivo. Further experiments using GMB animal models corroborated the ability of Pep#11 and Pep#26 in disrupting MSI1/AGO2 interaction and consequently anti-tumorigenicity and prolonged survival rates. These striking therapeutic efficacies orchestrated by the synthetic peptides were attributed to the decoy function to C-terminal MSI1, especially in malignant brain tumors and glioblastoma.




Cancer Research,Oncology

Reference61 articles.

1. Peptide decoys: a new technology offering therapeutic opportunities for breast cancer

2. Targeting cancer with kinase inhibitors

3. Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy

4. A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer;Yazdi;Avicenna J. Med. Biotechnol.,2015

5. A systematic review of dual targeting in HER2-positive breast cancer







Copyright © 2019-2022 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3